Alto Neuroscience (ANRO) Retained Earnings (2023 - 2026)
Alto Neuroscience (ANRO) posted Retained Earnings of $13000.0 for Q1 2026, down 100.0% sequentially from $352.8 million in Q4 2025, and down 7.14% YoY from $14000.0 in Q1 2025.
Alto Neuroscience (ANRO) Retained Earnings (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Retained Earnings for 4 years, with the latest figure at $13000.0 in Q1 2026.
- Quarterly Retained Earnings fell 7.14% year-over-year to $13000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13000.0 (down 7.14% YoY) and the FY2025 annual result came in at $352.8 million, up 354.89% from the prior year.
- Retained Earnings declined to $13000.0 in Q1 2026 per ANRO's latest filing, from $352.8 million in the prior quarter.
- Over five years, Retained Earnings peaked at $352.8 million in Q4 2025 and troughed at -$185.5 million in Q3 2025.
- A 4-year average of -$7.0 million and a median of -$45.2 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings tumbled 175084.81% in 2024, then surged 354.89% in 2025.
- Over 4 years, Retained Earnings stood at -$79000.0 in 2023, then sank by 175084.81% to -$138.4 million in 2024, then soared by 354.89% to $352.8 million in 2025, then slumped by 100.0% to $13000.0 in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $13000.0, $352.8 million, and -$185.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | 474.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 474.74 Mn |
| Mar 31, 2026 | 13,000.00 |
| Dec 31, 2025 | 352.75 Mn |
| Sep 30, 2025 | -185.50 Mn |
| Jun 30, 2025 | -171.30 Mn |
| Mar 31, 2025 | 14,000.00 |
| Dec 31, 2024 | -138.40 Mn |
| Sep 30, 2024 | -123.20 Mn |
| Jun 30, 2024 | 286.27 Mn |
| Mar 31, 2024 | -90.38 Mn |
| Dec 31, 2023 | -79,000.00 |